Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T12:21:19.185Z Has data issue: false hasContentIssue false
  • English
  • Français

Trifluoperazine (“Stelazine”) a Controlled Clinical Trial in Chronic Schizophrenia

Published online by Cambridge University Press:  08 February 2018

W. J. Stanley  and
D. Walton
W. J. Stanley
Affiliation:
Winwick Hospital
D. Walton
Affiliation:
Winwick Hospital
Get access Rights & Permissions [Opens in a new window]

Extract

So many new compounds are now being introduced for the treatment of psychiatric disorders that it is difficult for the clinician to assess the accuracy of the claims made for them. If a form of therapy is one hundred per cent. effective in a disease which was previously one hundred per cent. fatal, for example vitamin B12 in pernicious anaemia, the question of a controlled trial does not arise. But even the manufacturers do not claim such a degree of effectiveness for drugs advocated for the treatment of mental illnesses, and in addition the natural course of such illnesses is very variable, so that it is essential that clinical trials of these drugs should be controlled. Foulds (1958) has reviewed British and American clinical trials of drugs in psychiatry during the years 1951 to 1956, and has shown that the less controlled a trial, the more likely it is to result in a favourable report on the drug being tested, presumably because of bias on the part of the clinician. Forrester (1958), however, on the basis of a completely uncontrolled trial of Stelazine on only twenty-five patients, concluded that “the amount of improvement in a few cases was not sufficient to encourage the further use of the drug”.

Type
Original Articles
Information
Journal of Mental Science , Volume 107 , Issue 447 , March 1961 , pp. 250 - 257
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Forrester, M. E., Brit. Med. J., 1958, ii, 90.CrossRefGoogle Scholar
Foulds, G. A., J. Ment. Sci., 1958, 104, 435.Google Scholar
KLIMCZYNSKI, J. J. J. T., in Trifluoperazine, 1958. Philadelphia: Lea and Febiger.Google Scholar
Lucerno, R. J., and Mayer, B. T., J. Clin. Psychol., 1951, 7, 250.3.0.CO;2-G>CrossRefGoogle Scholar
Madgwick, J. R. A., McNeill, D. L., Driver, M., and Preston, G. C., J. Ment. Sci., 1958 104, 1195.CrossRefGoogle Scholar
May, A. R., Whiteley, J. S., and Gradwell, B. G., ibid., 1959, 105, 1959.Google Scholar
Oakley, D. P., Brit. Med. J., 1959, i, 862.CrossRefGoogle Scholar
Paulson, G., J. Ment. Sci., 1959, 105, 798.CrossRefGoogle Scholar
Rudy, L. H., Rinaldi, F., Costa, E., Himwich, H. E., Tuteur, W., and Glotzer, J., Amer. J. Psychiat., 1958, 114 (8), 747.CrossRefGoogle Scholar
Siegel, S., Nonparametric Statistics for the Behavioural Sciences, 1957. London: McGraw-Hill.Google Scholar
Wittenborn, J. R., Wittenborn Psychiatric Rating Scales, 1955. New York: The Psychological Corporation.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.